Ozempic vs Victoza
Ozempic and Victoza are both GLP-1 receptor agonists, but Ozempic is dosed weekly while Victoza requires daily injections, and Ozempic has demonstrated superior weight loss results (average 15% body weight reduction vs. 5-6% for Victoza) in clinical trials.
Ozempic (semaglutide)
Weekly injectable GLP-1 receptor agonist for type 2 diabetes with potent weight loss and cardiovascular benefits.
Patients with type 2 diabetes seeking maximum weight loss and cardiovascular protection who prioritize convenient once-weekly dosing.
Victoza (liraglutide)
Daily injectable GLP-1 receptor agonist for type 2 diabetes with established long-term safety record.
Patients new to GLP-1 therapy seeking established safety data, those unable to afford newer alternatives, or patients with moderate weight loss goals who tolerate daily injections.
Quick Answer
AI SummaryOzempic and Victoza are both GLP-1 receptor agonists, but Ozempic is dosed weekly while Victoza requires daily injections, and Ozempic has demonstrated superior weight loss results (average 15% body weight reduction vs. 5-6% for Victoza) in clinical trials.
Our Verdict
AI-assistedChoose Ozempic if you prioritize maximum weight loss, need better cardiovascular protection, and prefer weekly dosing for convenience and compliance. Choose Victoza if you have a longer history with the medication class, prefer a more conservative approach for your first GLP-1 therapy, or have insurance limitations, though Ozempic's superior efficacy makes it the preferred first-line option for most patients with type 2 diabetes.
Was this verdict helpful?
Choose Ozempic (semaglutide) if
Best pickPatients with type 2 diabetes seeking maximum weight loss and cardiovascular protection who prioritize convenient once-weekly dosing.
Choose Victoza (liraglutide) if
Patients new to GLP-1 therapy seeking established safety data, those unable to afford newer alternatives, or patients with moderate weight loss goals who tolerate daily injections.
Track this comparison
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
Key Differences at a Glance
- Injection Frequency:✓ Ozempic (semaglutide) wins(Once weekly vs Once daily)
- Average Weight Loss:✓ Ozempic (semaglutide) wins(15% body weight (SUSTAIN-6 trial) vs 5-6% body weight)
- FDA Indication for Type 2 Diabetes:Yes, approved 2017 vs Yes, approved 2010
Key Facts & Figures
26 numeric metrics compared
| Metric | Ozempic (semaglutide) | Victoza (liraglutide) | Ratio |
|---|---|---|---|
| Dosing Frequency(times per week) | 1x weekly | — | — |
| Time to Maximum Dose(weeks) | 4 weeks | — | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | $750 | +47% |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — | — |
| FDA Approval Year | 2017 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — | — |
| Nausea Incidence Rate(%) | 25-40% | — | — |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | 6% | +267% |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | 1.2-1.5% | +22% |
| Half-Life Duration(hours) | 168 hours (7 days) | 13 hours | +1192% |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | $950 | +16% |
| Time to Reach Steady State(weeks) | 4-5 weeks | 1-2 weeks | +200% |
| GI Side Effect Incidence Rate(%) | 32% | 26% | +23% |
| Years on Market(years) | 11 years (since 2013) | 15 years (since 2009) | -27% |
| Injection Frequency | Once weekly | Once daily | -86% |
| Average Body Weight Loss(%) | 15% | 5.6% | +168% |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | 13% (LEADER) | +100% |
| Maximum Approved Dose(mg) | 2.4 mg weekly | 1.8 mg daily | +33% |
| Years Since FDA Approval(years) | 7 years (2017) | 16 years (2010) | -56% |
| Nausea Incidence in Trials(%) | 25-39% | 20-30% | +28% |
Sourced from publicly available data · Jul 2026
Key Differences
7 attributes compared head-to-head
- Once weeklyInjection FrequencyOnce daily
- 15% body weight (SUSTAIN-6 trial)Average Weight Loss5-6% body weight
- Yes, approved 2017FDA Indication for Type 2 DiabetesYes, approved 2010
- Long-acting (semaglutide)GLP-1 Agonist ClassShort-acting (liraglutide)
- SUSTAIN-6: 26% reduction in cardiovascular eventsCardiovascular Outcome TrialLEADER: 13% reduction in cardiovascular events
- 2.4 mgMaximum Weekly Dose1.8 mg daily (12.6 mg weekly equivalent)
- 2017 (7 years newer)Time to Market2010
- Injection Frequency
Ozempic (semaglutide)
Once weekly
Victoza (liraglutide)
Once daily
- Average Weight Loss
Ozempic (semaglutide)
15% body weight (SUSTAIN-6 trial)
Victoza (liraglutide)
5-6% body weight
- FDA Indication for Type 2 Diabetes
Ozempic (semaglutide)
Yes, approved 2017
Victoza (liraglutide)
Yes, approved 2010
- GLP-1 Agonist Class
Ozempic (semaglutide)
Long-acting (semaglutide)
Victoza (liraglutide)
Short-acting (liraglutide)
- Cardiovascular Outcome Trial
Ozempic (semaglutide)
SUSTAIN-6: 26% reduction in cardiovascular events
Victoza (liraglutide)
LEADER: 13% reduction in cardiovascular events
- Maximum Weekly Dose
Ozempic (semaglutide)
2.4 mg
Victoza (liraglutide)
1.8 mg daily (12.6 mg weekly equivalent)
- Time to Market
Ozempic (semaglutide)
2017 (7 years newer)
Victoza (liraglutide)
2010
Full Comparison
| Attribute | Ozempic (semaglutide) | Victoza (liraglutide) |
|---|---|---|
| Average Weight Loss(%) | 15% | — |
| Time to Maximum Dose(weeks) | 4 weeks | — |
| Maximum Weight Loss at Highest Approved Dose(%) | 22% | 6% |
| A1C Reduction (Average)(mmol/mol) | 1.5-1.8% | 1.2-1.5% |
| Average Body Weight Loss(%) | 15% | 5.6% |
| Dosing Frequency(times per week) | 1x weekly | — |
| FDA Approval Year (for weight loss)(year) | 2021 (Wegovy) | — |
| Average Monthly Cost (Uninsured)(USD) | $1,100 | $750 |
| Average Monthly Cost (Without Insurance)(USD) | $1,100 | $950 |
| Clinical Trial Duration(weeks) | 68 weeks (STEP) | — |
| FDA Approval Year | 2017 | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| Maximum Approved Dose(mg) | 2.4 mg weekly | 1.8 mg daily |
| HbA1c Reduction (Type 2 Diabetes)(%) | 1.5-1.8% | — |
| Average Weight Loss in Pivotal Trial(lbs) | 4-6 lbs (secondary outcome) | — |
| Nausea Incidence Rate(%) | 25-40% | — |
| GI Side Effect Incidence Rate(%) | 32% | 26% |
| Nausea Incidence in Trials(%) | 25-39% | 20-30% |
| Insurance Coverage Rate for Primary Indication(%) | 85% (diabetes) | — |
| CVOT Cardiovascular Risk Reduction(%) | 26% | — |
| Trial Duration for Primary Endpoint(weeks) | 52 weeks (SUSTAIN-6) | — |
| Half-Life Duration(hours) | 168 hours (7 days) | 13 hours |
| Time to Reach Steady State(weeks) | 4-5 weeks | 1-2 weeks |
| Years on Market(years) | 11 years (since 2013) | 15 years (since 2009) |
| Injection Frequency | Once weekly | Once daily |
| Cardiovascular Event Reduction(%) | 26% (SUSTAIN-6) | 13% (LEADER) |
| Years Since FDA Approval(years) | 7 years (2017) | 16 years (2010) |
Pros & Cons
10 pros·6 cons across both
Ozempic (semaglutide)
Pros
- Once-weekly injection increases compliance vs. daily alternatives
- 15% average body weight reduction in SUSTAIN-6 clinical trial
- 26% relative reduction in major cardiovascular events (SUSTAIN-6)
- Effective A1C reduction to <7% in majority of users
- Pre-filled pen device with simple injection mechanism
Cons
- Higher cost with average monthly prices $900-$1,300 before insurance
- Higher incidence of gastrointestinal side effects (nausea 25-39% of users)
- Risk of pancreatitis and C-cell thyroid tumors in animal studies (black box warning applies to GLP-1 class)
Victoza (liraglutide)
Pros
- FDA approved since 2010 with 14+ years of real-world safety data
- 13% relative reduction in major cardiovascular events (LEADER trial)
- 5-6% average body weight reduction in clinical trials
- Lower cost in many insurance plans (average $600-$900 monthly)
- Proven effective for both type 2 diabetes and chronic weight management (Saxenda formulation)
Cons
- Requires daily injections reducing compliance vs. weekly alternatives
- Modest weight loss compared to newer long-acting GLP-1 agonists
- Gastrointestinal side effects present in 20-30% of users, though potentially less severe than Ozempic
Frequently Asked Questions
5 questions
Ozempic produces substantially more weight loss, with clinical trials (SUSTAIN-6) showing 15% average body weight reduction compared to Victoza's 5-6% reduction. This difference is significant enough that many endocrinologists now prefer Ozempic as first-line therapy for patients whose primary goal includes weight management alongside diabetes control.
Resources & Learn More
Curated sources to dive deeper
Where to Buy
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more
Wikipedia
Related Comparisons
12 more to explore
- OvsV
Ozempic vs Victoza
health - OvsS
Ozempic vs Saxenda
health - OvsZ
Ozempic vs Zepbound
health - YvsP
Yoga vs Pilates
health - IvsA
Ibuprofen vs Acetaminophen
health - IvsB
Invisalign vs Braces
health - LvsP
LASIK vs PRK
health - WvsC
Whey Protein vs Casein Protein
health - CvsG
CrossFit vs Gym Training
health - FvsC
Flu Shot vs COVID Vaccine
health - OvsN
Organic Food vs Non-Organic Food
health - TvsM
Therapy vs Medication
health
Related Articles
1 article
Explore More
Related comparisons and categories